JP7089649B2 - 非ペプチドオキシトシン受容体アゴニスト - Google Patents

非ペプチドオキシトシン受容体アゴニスト Download PDF

Info

Publication number
JP7089649B2
JP7089649B2 JP2019531447A JP2019531447A JP7089649B2 JP 7089649 B2 JP7089649 B2 JP 7089649B2 JP 2019531447 A JP2019531447 A JP 2019531447A JP 2019531447 A JP2019531447 A JP 2019531447A JP 7089649 B2 JP7089649 B2 JP 7089649B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500924A (ja
Inventor
マイケル・カッシオウ
ウィリアム・ヨルゲンセン
エリン・ウェリー
トリスタン・リーキー
マイケル・ボーウェン
イアイン・マックレガー
Original Assignee
キノシス・セラピューティクス・ピーティーワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905126A external-priority patent/AU2016905126A0/en
Application filed by キノシス・セラピューティクス・ピーティーワイ・リミテッド filed Critical キノシス・セラピューティクス・ピーティーワイ・リミテッド
Publication of JP2020500924A publication Critical patent/JP2020500924A/ja
Priority to JP2022078250A priority Critical patent/JP2022097655A/ja
Application granted granted Critical
Publication of JP7089649B2 publication Critical patent/JP7089649B2/ja
Priority to JP2024091625A priority patent/JP2024107136A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
JP2019531447A 2016-12-12 2017-12-12 非ペプチドオキシトシン受容体アゴニスト Active JP7089649B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022078250A JP2022097655A (ja) 2016-12-12 2022-05-11 非ペプチドオキシトシン受容体アゴニスト
JP2024091625A JP2024107136A (ja) 2016-12-12 2024-06-05 非ペプチドオキシトシン受容体アゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905126A AU2016905126A0 (en) 2016-12-12 Non-peptide oxytocin receptor agonists
AU2016905126 2016-12-12
PCT/AU2017/051371 WO2018107216A1 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078250A Division JP2022097655A (ja) 2016-12-12 2022-05-11 非ペプチドオキシトシン受容体アゴニスト

Publications (2)

Publication Number Publication Date
JP2020500924A JP2020500924A (ja) 2020-01-16
JP7089649B2 true JP7089649B2 (ja) 2022-06-23

Family

ID=62557695

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019531447A Active JP7089649B2 (ja) 2016-12-12 2017-12-12 非ペプチドオキシトシン受容体アゴニスト
JP2022078250A Pending JP2022097655A (ja) 2016-12-12 2022-05-11 非ペプチドオキシトシン受容体アゴニスト
JP2024091625A Pending JP2024107136A (ja) 2016-12-12 2024-06-05 非ペプチドオキシトシン受容体アゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022078250A Pending JP2022097655A (ja) 2016-12-12 2022-05-11 非ペプチドオキシトシン受容体アゴニスト
JP2024091625A Pending JP2024107136A (ja) 2016-12-12 2024-06-05 非ペプチドオキシトシン受容体アゴニスト

Country Status (19)

Country Link
US (2) US11491165B2 (https=)
EP (2) EP4494705A3 (https=)
JP (3) JP7089649B2 (https=)
KR (1) KR102561721B1 (https=)
CN (1) CN110248944A (https=)
AU (1) AU2017377653B2 (https=)
BR (1) BR112019012049A2 (https=)
CA (1) CA3046809A1 (https=)
DK (1) DK3551631T3 (https=)
ES (1) ES3001195T3 (https=)
FI (1) FI3551631T3 (https=)
HU (1) HUE070078T2 (https=)
IL (1) IL267276B2 (https=)
MX (1) MX2019006942A (https=)
PL (1) PL3551631T3 (https=)
PT (1) PT3551631T (https=)
RU (1) RU2019120162A (https=)
SI (1) SI3551631T1 (https=)
WO (1) WO2018107216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079953A1 (en) * 2018-11-23 2022-03-17 The University Of Sydney Methods for management of weight
KR20220063198A (ko) * 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2023552485A (ja) * 2020-12-14 2023-12-15 キノシス・セラピューティクス・ピーティーワイ・リミテッド オキシトシン受容体モジュレーター
AU2022240104A1 (en) * 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500317A (ja) 2001-06-25 2005-01-06 フェリング ベスローテン フェンノートシャップ オキシトシンアゴニスト
JP2005501858A (ja) 2001-08-16 2005-01-20 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬としてのジアザシクロアルカン
JP2006517530A (ja) 2003-02-14 2006-07-27 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
JP2007504263A (ja) 2003-09-05 2007-03-01 フェリング ベスローテン フェンノートシャップ オキシトシン作働薬としてのピペラジン類
JP2008510684A (ja) 2004-08-24 2008-04-10 フェリング ベスローテン フェンノートシャップ バソプレッシンＶ１ａ拮抗薬
WO2008103367A2 (en) 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, proapoptotic compounds discovered by same
JP2012519161A (ja) 2009-02-27 2012-08-23 ヴァンティア リミテッド バソプレッシン受容体Ｖ１ａ拮抗薬としての１，４−ジ置換ピペリジン
WO2016089830A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
JP2018525351A (ja) 2015-07-06 2018-09-06 ザ・ユニヴァーシティ・オブ・シドニー 社会性障害および物質使用障害を治療するための治療用化合物および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US7342112B2 (en) * 2003-07-01 2008-03-11 Ppg Industries Ohio, Inc. Photochromic compounds
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
AU2006306547A1 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500317A (ja) 2001-06-25 2005-01-06 フェリング ベスローテン フェンノートシャップ オキシトシンアゴニスト
JP2005501858A (ja) 2001-08-16 2005-01-20 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬としてのジアザシクロアルカン
JP2006517530A (ja) 2003-02-14 2006-07-27 フェリング ベスローテン フェンノートシャップ オキシトシン作動薬およびバソプレッシン拮抗薬としてのベンズアミド誘導体
JP2007504263A (ja) 2003-09-05 2007-03-01 フェリング ベスローテン フェンノートシャップ オキシトシン作働薬としてのピペラジン類
JP2008510684A (ja) 2004-08-24 2008-04-10 フェリング ベスローテン フェンノートシャップ バソプレッシンＶ１ａ拮抗薬
WO2008103367A2 (en) 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, proapoptotic compounds discovered by same
JP2012519161A (ja) 2009-02-27 2012-08-23 ヴァンティア リミテッド バソプレッシン受容体Ｖ１ａ拮抗薬としての１，４−ジ置換ピペリジン
WO2016089830A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
JP2018525351A (ja) 2015-07-06 2018-09-06 ザ・ユニヴァーシティ・オブ・シドニー 社会性障害および物質使用障害を治療するための治療用化合物および組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANTZ, Marie-Celine，Journal of Medicinal Chemistry，2010年，53，1546-1562
JORGENSEN, William T.，European Journal of Medicinal Chemistry，2016年，108，730-740
KARPENKO, Iuliia，Journal of Medicinal Chemistry，2015年，58，2547-2552
REEKIE, Tristan A.，Tetrahedron Letters，2014年，55，4568-4571

Also Published As

Publication number Publication date
CN110248944A (zh) 2019-09-17
KR102561721B1 (ko) 2023-07-28
US20200000823A1 (en) 2020-01-02
IL267276B1 (en) 2024-05-01
BR112019012049A2 (pt) 2019-11-12
EP3551631A1 (en) 2019-10-16
AU2017377653B2 (en) 2022-04-21
JP2024107136A (ja) 2024-08-08
EP3551631A4 (en) 2020-07-15
JP2022097655A (ja) 2022-06-30
RU2019120162A (ru) 2021-01-12
ES3001195T3 (es) 2025-03-04
PL3551631T3 (pl) 2025-03-24
HUE070078T2 (hu) 2025-05-28
IL267276B2 (en) 2024-09-01
DK3551631T3 (en) 2025-02-17
US20230330103A1 (en) 2023-10-19
CA3046809A1 (en) 2018-06-21
MX2019006942A (es) 2019-10-21
EP3551631B1 (en) 2024-11-13
FI3551631T3 (fi) 2025-01-16
EP4494705A3 (en) 2025-04-02
EP3551631B9 (en) 2025-02-26
JP2020500924A (ja) 2020-01-16
US11491165B2 (en) 2022-11-08
RU2019120162A3 (https=) 2021-01-28
WO2018107216A1 (en) 2018-06-21
IL267276A (en) 2019-08-29
PT3551631T (pt) 2024-12-10
SI3551631T1 (sl) 2025-03-31
AU2017377653A1 (en) 2019-07-11
KR20190091534A (ko) 2019-08-06
EP4494705A2 (en) 2025-01-22
NZ754890A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
JP2022097655A (ja) 非ペプチドオキシトシン受容体アゴニスト
US11708327B2 (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
KR101769999B1 (ko) Ｎｍｄａ 수용체 조절제 및 그의 용도
TW201121949A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
MX2013008111A (es) Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos.
JPWO2007102531A1 (ja) 併用薬
KR20010014279A (ko) 뮤 오피오이드 화합물의 호흡 저하 및 수반되는 부작용을감소시키기 위한 조성물 및 그 방법
TW201321353A (zh) 胺基甲酸酯／尿素衍生物
TW201609698A (zh) 三環磺醯胺衍生物
JP2000501432A (ja) 新規インドール―２，３―ジオン―３―オキシム誘導体
TW200824689A (en) Novel compounds
CN118252829A (zh) Crf受体拮抗剂及使用方法
CN110461835A (zh) 异噁唑甲酰胺化合物及其用途
ITMI951900A1 (it) Derivati idroisochinolinici sostituiti
JP2007532526A (ja) ピラゾロ［４，３−ｄ］ピリミジン類
JP4588444B2 (ja) ジアザビシクロノナン及び−デカン誘導体並びにこれをオピオイドレセプターリガンドとして使用する方法
KR20220034038A (ko) Bcl-2 억제제의 나노입자 제형
US20240208907A1 (en) Gpr52 modulators and methods of use
EP4196471A1 (en) Oxopyrrolidine urea fpr2 agonists
JPWO2004080965A1 (ja) ニューロペプチドｆｆ受容体拮抗剤
HK40014275A (en) Non-peptide oxytocin receptor agonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220411

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220511

R150 Certificate of patent or registration of utility model

Ref document number: 7089649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250